Evidence map›Paper›PMID 29176798›Full record

ArticlePloS one2017

The scavenging chemokine receptor ACKR2 has a significant impact on acute mortality rate and early lesion development after traumatic brain injury.

Thomas M Woodcock, Tony Frugier, Tan Thanh Nguyen, Bridgette Deanne Semple, Nicole Bye, Matteo Massara, Benedetta Savino, Roberta Besio, Cristina Sobacchi, Massimo Locati and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Thomas M WoodcockNational Trauma Research Institute, The Alfred Hospital, Melbourne, Australia.
Tony FrugierDepartment of Pharmacology and Therapeutics School of Biomedical Sciences, The University of Melbourne, Melboune, Australia.
Tan Thanh NguyenNational Trauma Research Institute, The Alfred Hospital, Melbourne, Australia.
Bridgette Deanne SempleDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
Nicole ByeDivision of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia.
Matteo MassaraHumanitas Clinical and Research Center, Rozzano, Italy.
Benedetta SavinoHumanitas Clinical and Research Center, Rozzano, Italy.
Roberta BesioDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Cristina SobacchiHumanitas Clinical and Research Center, Rozzano, Italy.
Massimo LocatiHumanitas Clinical and Research Center, Rozzano, Italy.ORCID http://orcid.org/0000-0003-3077-590X
Maria Cristina Morganti-KossmannDepartment of Epidemiology and Preventive Medicine, and Australian New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Humanitas University · ITThe Alfred Hospital · AUBarrow Neurological Institute · USThe Royal Melbourne Hospital · AUThe University of Melbourne · AUUniversity of Pavia · ITUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The atypical chemokine receptor ACKR2 promotes resolution of acute inflammation by operating as a scavenger receptor for inflammatory CC chemokines in several experimental models of inflammatory disorders, however its role in the brain remains unclear. Based on our previous reports of increased expression of inflammatory chemokines and their corresponding receptors following traumatic brain injury (TBI), we hypothesised that ACKR2 modulates neuroinflammation following brain trauma and that its deletion exacerbates cellular inflammation and chemokine production. We demonstrate increased CCL2 and ACKR2 mRNA expression in post-mortem human brain, whereby ACKR2 mRNA levels correlated with later times post-TBI. This data is consistent with the transient upregulation of ACKR2 observed in mouse brain after closed head injury (CHI). As compared to WT animals, ACKR2-/- mice showed a higher mortality rate after CHI, while the neurological outcome in surviving mice was similar. At day 1 post-injury, ACKR2-/- mice displayed aggravated lesion volume and no differences in CCL2 expression and macrophage recruitment relative to WT mice. Reciprocal regulation of ACKR2 and CCL2 expression was explored in cultured astrocytes, which are recognized as the major source of CCL2 and also express ACKR2. ACKR2 mRNA increased as early as 2 hours after an inflammatory challenge in WT astrocytes. As expected, CCL2 expression also dramatically increased at 4 hours in WT astrocytes but was significantly lower in ACKR2-/- astrocytes, possibly indicating a co-regulation of CCL2 and ACKR2 in these cells. Conversely, in vivo, CCL2 mRNA/protein levels were increased similarly in ACKR2-/- and WT brains at 4 and 12 hours after CHI, in line with the lack of differences in cerebral macrophage recruitment and neurological recovery. In conclusion, ACKR2 is induced after TBI and has a significant impact on mortality and lesion development acutely following CHI, while its role in chemokine expression, macrophage activation, brain pathology, and neurological recovery at later time-points is minor. Concordant to evidence in multiple sclerosis experimental models, our data corroborate a distinct role for ACKR2 in cerebral inflammatory processes compared to its reported functions in peripheral tissues.

Indexed as

AnimalsAstrocytesBone and BonesBrainBrain Injuries, TraumaticCells, CulturedChemokine CCL2Chemokine Receptor D6Gene DeletionHumansInflammationMacrophagesMaleMice, Inbred C57BLMortalityReceptors, ChemokineACKR2 protein, humanAckr2 protein, mouseChemokine CCL2Chemokine Receptor D6Receptors, ChemokineRNA, Messenger

Identifiers

PMID29176798
PMCPMC5703564
OpenAlexW2769774984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.